See more : Ninety One Group (NINTF) Income Statement Analysis – Financial Results
Complete financial analysis of Bavarian Nordic A/S (BVNKF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bavarian Nordic A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Carna Biosciences, Inc. (CBIXF) Income Statement Analysis – Financial Results
- Taiga Building Products Ltd. (TBL.TO) Income Statement Analysis – Financial Results
- Mitsui Fudosan Co., Ltd. (MTSFF) Income Statement Analysis – Financial Results
- Sailun Group Co., Ltd. (601058.SS) Income Statement Analysis – Financial Results
- Quantum Build-Tech Limited (QUANTBUILD.BO) Income Statement Analysis – Financial Results
Bavarian Nordic A/S (BVNKF)
About Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.06B | 3.15B | 1.90B | 1.85B | 662.49M | 500.62M | 1.37B | 1.01B | 1.02B | 1.22B | 1.21B | 1.02B | 523.60M | 314.07M | 74.78M | 208.81M | 332.10M | 175.29M | 247.60M | 164.78M | 504.64M | 121.08M | 0.00 |
| Cost of Revenue | 2.46B | 1.45B | 1.33B | 1.20B | 354.76M | 255.12M | 290.62M | 297.79M | 415.14M | 495.08M | 484.71M | 513.55M | 403.39M | 444.47M | 140.10M | 196.66M | 55.12M | 110.80M | 132.23M | 70.25M | 187.19M | 56.45M | 0.00 |
| Gross Profit | 4.60B | 1.70B | 570.32M | 657.29M | 307.73M | 245.50M | 1.08B | 708.95M | 605.42M | 721.73M | 727.80M | 503.08M | 120.21M | -130.40M | -65.32M | 12.15M | 276.99M | 64.50M | 115.37M | 94.53M | 317.45M | 64.62M | 0.00 |
| Gross Profit Ratio | 65.18% | 53.99% | 30.05% | 35.48% | 46.45% | 49.04% | 78.79% | 70.42% | 59.32% | 59.31% | 60.02% | 49.49% | 22.96% | -41.52% | -87.34% | 5.82% | 83.40% | 36.79% | 46.60% | 57.37% | 62.91% | 53.37% | 0.00% |
| Research & Development | 2.35B | 1.18B | 399.16M | 341.42M | 409.28M | 386.30M | 518.41M | 463.17M | 386.81M | 478.93M | 496.61M | 357.44M | 261.72M | 210.83M | 163.98M | 129.65M | 134.96M | 39.28M | 114.38M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 419.85M | 376.02M | 292.92M | 278.15M | 173.42M | 179.96M | 168.06M | 174.21M | 174.79M | 181.02M | 156.99M | 137.76M | 133.40M | 104.58M | 91.48M | 92.04M | -1.57M | -76.37M | 75.39M | 56.42M | 42.99M | 31.40M | 21.96M |
| Selling & Marketing | 331.58M | 212.93M | 191.78M | 285.78M | 53.48M | 33.73M | 39.88M | 38.56M | 42.27M | 45.11M | 40.78M | 39.57M | 33.35M | 28.28M | 20.41M | 0.00 | 2.58M | 77.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 751.43M | 588.96M | 484.70M | 563.93M | 226.89M | 213.68M | 207.94M | 212.77M | 217.06M | 226.13M | 197.77M | 177.32M | 166.75M | 132.86M | 111.89M | 92.04M | 1.00M | 819.00K | 75.39M | 56.42M | 42.99M | 31.40M | 21.96M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -627.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.11B | 1.77B | 883.86M | 277.70M | 636.18M | 599.98M | 726.34M | 675.94M | 603.87M | 705.06M | 694.38M | 534.76M | 428.48M | 343.69M | 275.87M | 235.53M | 342.01M | 268.26M | 235.14M | 176.85M | 103.41M | 91.27M | 93.48M |
| Cost & Expenses | 5.01B | 3.22B | 2.21B | 1.47B | 990.93M | 855.10M | 1.02B | 973.74M | 1.02B | 1.20B | 1.18B | 1.05B | 831.87M | 788.16M | 415.97M | 432.19M | 397.13M | 379.06M | 367.37M | 247.10M | 290.60M | 147.73M | 93.48M |
| Interest Income | 40.21M | 26.00K | 1.74M | 193.00K | 602.00K | 842.00K | 644.00K | 272.00K | 38.00K | 12.00K | 29.00K | 667.00K | 21.65M | 4.19M | 7.76M | 40.09M | 25.71M | 4.36M | 19.67M | 9.77M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 105.52M | 119.69M | 152.06M | 177.00M | 18.49M | 14.53M | 5.68M | 7.06M | 6.53M | 6.28M | 6.49M | 7.96M | 9.76M | 13.54M | 17.81M | 40.09M | 2.13M | 2.27M | 16.32M | 4.17M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 553.82M | 399.25M | 387.69M | 344.08M | 57.05M | 41.64M | 106.81M | 44.08M | 43.53M | 44.95M | 46.22M | 56.45M | 53.88M | 49.74M | 49.23M | 48.34M | 40.14M | 17.95M | 15.39M | 0.00 | 12.93K | 5.13M | 3.60M |
| EBITDA | 2.14B | 395.40M | 85.94M | 819.13M | -269.21M | -300.47M | 345.09M | 91.98M | 127.69M | 115.58M | 58.92M | 10.54M | -234.24M | -420.16M | -273.23M | -175.05M | -36.06M | -184.58M | -84.71M | -82.32M | 214.05M | -21.52M | -89.88M |
| EBITDA Ratio | 30.33% | 12.55% | 6.59% | 43.72% | -39.15% | -55.51% | 25.19% | 11.20% | 12.45% | 5.40% | 5.28% | 2.69% | -44.45% | -133.78% | -353.15% | -83.83% | -2.48% | -105.30% | -34.21% | -49.96% | 42.42% | -17.77% | 0.00% |
| Operating Income | 1.50B | -3.85M | -263.31M | 449.62M | -316.43M | -319.51M | 307.56M | 67.34M | 83.51M | 20.72M | 17.84M | -29.08M | -286.62M | -469.90M | -313.32M | -223.39M | -48.36M | -202.53M | -100.10M | -82.32M | 214.04M | -26.65M | -93.48M |
| Operating Income Ratio | 21.28% | -0.12% | -13.87% | 24.27% | -47.76% | -63.82% | 22.45% | 6.69% | 8.18% | 1.70% | 1.47% | -2.86% | -54.74% | -149.61% | -418.98% | -106.98% | -14.56% | -115.54% | -40.43% | -49.96% | 42.41% | -22.01% | 0.00% |
| Total Other Income/Expenses | -19.60M | -260.83M | -191.12M | -97.61M | -16.30M | -2.15M | -50.91M | 6.54M | 76.08M | 47.69M | 78.04M | -17.04M | 11.88M | -9.35M | 10.05M | 26.25M | -2.13M | -2.27M | -16.32M | 5.60M | 3.59M | 936.00K | 2.54M |
| Income Before Tax | 1.48B | -331.61M | -454.43M | 281.98M | -344.75M | -356.64M | 302.28M | 39.55M | 77.63M | 64.36M | 6.20M | -48.73M | -296.38M | -483.44M | -331.13M | -183.30M | -50.49M | -204.79M | -116.42M | -76.72M | 217.63M | -25.71M | -90.94M |
| Income Before Tax Ratio | 21.00% | -10.52% | -23.94% | 15.22% | -52.04% | -71.24% | 22.06% | 3.93% | 7.61% | 5.29% | 0.51% | -4.79% | -56.60% | -153.93% | -442.79% | -87.78% | -15.20% | -116.83% | -47.02% | -46.56% | 43.13% | -21.24% | 0.00% |
| Income Tax Expense | 7.75M | 15.77M | 10.35M | 4.46M | 2.03M | 5.29M | 120.94M | 8.95M | 18.20M | 38.42M | 52.93M | 191.28M | 27.96M | 93.53M | 64.86M | 32.94M | 13.01M | -43.86M | -21.69M | -23.71M | 67.06M | -95.83M | 1.14M |
| Net Income | 1.48B | -347.38M | -464.78M | 277.52M | -346.78M | -361.93M | 181.34M | 30.60M | 59.43M | 25.94M | -46.73M | -240.00M | -268.42M | -389.91M | -266.28M | -150.36M | -59.97M | -158.04M | -94.73M | -53.01M | 150.57M | 70.12M | -92.09M |
| Net Income Ratio | 20.89% | -11.03% | -24.49% | 14.98% | -52.34% | -72.30% | 13.24% | 3.04% | 5.82% | 2.13% | -3.85% | -23.61% | -51.26% | -124.15% | -356.07% | -72.01% | -18.06% | -90.16% | -38.26% | -32.17% | 29.84% | 57.91% | 0.00% |
| EPS | 19.20 | -4.93 | -7.37 | 5.13 | -8.50 | -8.88 | 4.54 | 0.80 | 1.69 | 0.78 | -1.42 | -7.28 | -10.24 | -26.50 | -20.89 | -9.94 | -4.14 | -12.38 | -8.65 | -5.64 | 15.02 | 7.91 | -13.55 |
| EPS Diluted | 19.23 | -4.93 | -7.37 | 5.13 | -8.50 | -8.88 | 4.50 | 0.80 | 1.64 | 0.76 | -1.42 | -7.28 | -10.24 | -26.50 | -20.89 | -9.94 | -4.14 | -12.38 | -8.65 | -5.64 | 15.02 | 7.91 | -13.51 |
| Weighted Avg Shares Out | 76.83M | 70.42M | 63.10M | 54.05M | 40.81M | 40.77M | 39.98M | 38.04M | 35.14M | 33.32M | 32.99M | 32.99M | 26.21M | 14.71M | 12.75M | 15.13M | 14.47M | 12.77M | 10.95M | 9.40M | 10.02M | 8.87M | 6.79M |
| Weighted Avg Shares Out (Dil) | 76.71M | 70.42M | 63.10M | 54.05M | 40.81M | 40.77M | 40.30M | 38.34M | 36.16M | 33.93M | 32.99M | 32.99M | 26.21M | 14.71M | 12.75M | 15.13M | 14.47M | 12.77M | 10.95M | 9.40M | 10.02M | 8.87M | 6.82M |
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN® smallpox vaccine to the strategic reserve within the European Union (EU) in 2025....
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA) for the licensure of its...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, April 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.
Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S
COPENHAGEN, Denmark, April 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results:
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland
COPENHAGEN, Denmark, March 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved JYNNEOS® (MVA-BN) for active immunization against disease caused by smallpox, mpox and vaccinia viruses in adults 18...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, March 12, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in...
Bavarian Nordic A/S (BVNKF) Q4 2023 Earnings Call Transcript
Bavarian Nordic A/S (OTCPK:BVNKF) Q4 2023 Earnings Conference Call March 6, 2024 8:00 AM ET Company Participants Rolf Sorensen - Vice President of Investor Relations Paul Chaplin - President & Chief Executive Officer Henrik Juuel - Executive Vice President &...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, March 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in...
Bavarian Nordic Publishes Annual Report 2023
COPENHAGEN, Denmark, March 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2023. The consolidated, audited results were in line with the preliminary results, announced on February 21, 2024, and exceeded prior guidance. The full...
Bavarian Nordic's Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency
COPENHAGEN, Denmark, February 23, 2024 – Bavarian Nordic A/S (OMX: BAVA) (“the Company”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment for the upcoming Marketing Authorisation...
Source: https://incomestatements.info
Category: Stock Reports